EGFR and non-small cell lung carcinoma: As shown in Figure 2C, the meta-analysis revealed that compared with WBRT plus EGFR-TKIs for NSCLC patients with BM, the EGFR-TKIs alone treatment exhibited a superior intracranial PFS (HR = 1.30 [95% CI 1.03–1.65; P = 0.03]) (Figure 2C).